23 Jul, 2026
According to Straits Research, the global biobanking market valued at $59.98 billion in 2025, is projected to grow from $64.27 billion in 2026 to $113.05 billion by 2034 at a CAGR of 7.32% during the forecast period 2026–2034.
A biobank is a biorepository meant to collect and preserve biological materials used for diagnosis, biodiversity studies, and research. In addition, it is used to support the research of the most common types of genetic disorders to develop personalized medicines and maintain and update the database of diseases related to aging. It is a process of collecting different samples of body fluids or tissue and store for further use in research by pharmaceutical and biotechnology companies.
The rise in funding from private and government organizations for biobanking and the increase in application areas of bio-banked samples are the major factors that drive the growth of the global biobanking market. Genomic research activities act as a critical driving force in the global market. Furthermore, the government is taking multiple initiatives to support regenerative medicine research, which is expected to boost the market growth.
Private and government organizations are undertaking many clinical trials to widen the application of cord blood. Biobanking is gaining momentum owing to the developments in metagenomics, personalized medicine, genomics, proteomics, bioenergy, environmental remediation, disease biology, and allied fields. Moreover, biobanking is essential in supporting many types of contemporary research, such as genomics and personalized medicine, as it allows researchers to access data and biological samples, increasing the demand for biobanking products and services.
Various institutes are conducting numerous researches on the application of cord blood in different fields of science, which could benefit human health. Moreover, in 2020, Lund University in Sweden launched the world's largest biobank to understand and research the most common diseases such as Alzheimer's disease, Parkinson's disease, cardiovascular, and diabetes. Thus, an increase in research activities in such applications of cord blood has been witnessed in recent years, which is expected to boost the demand for cord blood, thereby fueling the market growth.
Biobanking is the fastest-growing sector of the healthcare industry. Individuals seek cutting-edge alternatives to conventional therapy to treat chronic ailments. Additionally, the global biobanking market is driven by rising demand. Applications for stem cell therapy are constantly being created due to new research and discoveries. Complex and untreatable diseases with existing medical techniques may be treated effectively using stem cell therapy. For instance, the launch of Stempeucel in India was made possible by a partnership between Stempeutics and Cipla Limited, a significant pharmaceutical business. The first cell therapy for the treatment of critical limb ischemia is called Stempeucel.
According to the World Health Organization (WHO), it was reported that more than 50,000 transplants are performed each year globally. Furthermore, developing countries such as India and China are expected to experience significant growth, owing to a surge in health care infrastructure, increase in affordability, and rise in awareness related to biobanking. Additionally, in June 2018, the German biobank Alliance, an organization of biobanks in Germany, launched a campaign to raise awareness about donating biomaterials such as blood, tissues, and other body fluids.
The developing regions such as Asia-Pacific and LAMEA are expected to witness notable growth, owing to a surge in healthcare infrastructure, increase in affordability, and rise in awareness related to chronic diseases and disorders. Besides, the surge in personal disposable income of the population and the rise in health care spending in developing regions are expected to offer potential growth opportunities for the global biobanking market.
The European biobanking market accounts for the highest share and is expected to grow at a CAGR of 5.6% during the forecast period. This is attributed to the early adoption of advanced technologies and increased awareness of biobanking among healthcare professionals and individuals in the R&D industry.
North America is the second-largest revenue contributor, with the US leading this market. North America dominated the biobanking market with a market share of 34.15% in 2025. This is attributed to the high acceptance of storing specimens such as cord blood in the US. Additionally, a rise in awareness among the population about the benefits of biobanking and increased investments for R&D in stem cell research boost the growth of companies providing cord blood preservation facilities, which, in turn, augments the development of the overall market.
sales@straitsresearch.com